Results 1 to 10 of about 899 (75)

Case report: 177Lu DOTA-TATE: a new scheme for the treatment of prostate neuroendocrine cancer. [PDF]

Front Oncol, 2023
BackgroundMost instances of small cell carcinoma originate from the lungs, while the gastrointestinal tract serves as a secondary site. Only a minuscule proportion of cases manifest within the urogenital system. Prostate small cell carcinoma (SCCP) represents an exceedingly uncommon pathological subtype within the realm of prostate cancer, displaying ...
Yu XY, Zhu YQ, Liu X, Tian R, Chen JJ, Liu GQ, Yang DY, Zhang XP, Li B, Zhao HJ, Li X.   +10 more
europepmc   +4 more sources

Toxicity and Tolerability of ¹⁷⁷Lu-DOTA-TATE PRRT with a Modified Administered Activity Protocol in NETs of Variable Origin - A Phase 2 Registry Study. [PDF]

Curr Radiopharm, 2022
Background: Peptide receptor radionuclide therapy (PRRT) has been recently approved for advanced, metastatic, or progressive neuroendocrine tumors (NETs). Objectives: This study reports the adverse events (AEs) observed with patient-tailored administered activity. Methods: Fifty-two PRRT naive patients were treated with 177Lu-DOTATATE.
Khatami A, Sistani G, Sutherland DEK, DeBrabandere S, Reid RH, Laidley DT.   +5 more
europepmc   +3 more sources

Somatostatin-receptor avidity of pancreatic neuroendocrine tumor thrombus in porto-caval venous systems on ^99mTc-Octreotide and posttherapeutic ¹⁷⁷Lu-DOTA-TATE scans. [PDF]

World J Nucl Med, 2021
AbstractA 62-year-old woman with a history of abdominal pain presented with multiple hepatic lesions and dilatation of portal, splenic and superior mesenteric veins on the magnetic resonance imaging referred for a 99mTc-octreotide scan. Accordingly, similar octreotide-avid lesions were found as well as an uptake in the epigastric region conforming to ...
Amoui M, Ahmadi R, Qutbi M, Asli IN.
europepmc   +5 more sources

Lutetium [¹⁷⁷Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study. [PDF]

Eur J Nucl Med Mol Imaging
Abstract Purpose Gastroenteropancreatic -neuroendocrine tumours (GEP-NETs) are commonly treated with surgical resection or long-term therapies for tumour growth control. Lutetium [177Lu]-DOTA-TATE was approved for the treatment of GEP-NETs after the phase III NETTER 1trial demonstrated improved progression free survival,
Lastoria S, Rodari M, Sansovini M, Baldari S, D'Agostini A, Cervino AR, Filice A, Salgarello M, Perotti G, Nieri A, Campana D, Pellerito RE, Pomposelli E, Gaudieri V, Storto G, Grana CM, Signore A, Boni G, Dondi F, Simontacchi G, Seregni E.   +20 more
europepmc   +4 more sources

SUN-329 177Lu-DOTA-TATE Treatment in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors: A Single-Center 7-Year Experience

J Endocr Soc, 2019
Introduction: Pancreatic neuroendocrine tumors (PNETs) frequently express somatostatin receptors on their cell membranes. These receptors are targets for therapy with Lutetium-177-labeled somatostatin analogs. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTA-TATE is a therapeutic option in patients with disease progression during first-line
Gouveia P, Ferreira G, Lucena Sampaio I, Duarte H.   +3 more
europepmc   +2 more sources

Predictive power of the post-treatment scans after the initial or first two courses of [¹⁷⁷Lu]-DOTA-TATE. [PDF]

EJNMMI Phys, 2018
The aim of this study was to evaluate the predictive power of the absorbed dose to kidneys after the first course of treatment with [177Lu]-DOTA-TATE for neuroendocrine tumors (NETs) on the cumulative kidney absorbed dose after 3 or 4 cycles of treatment. Post-treatment scans (PTS) are acquired after each cycle of peptide receptor radionuclide therapy (
Chicheportiche A, Grozinsky-Glasberg S, Gross DJ, Krausz Y, Salmon A, Meirovitz A, Freedman N, Godefroy J.   +7 more
europepmc   +5 more sources

Nöroendokrin tumörlerde 177Lu-DOTA-TATE tedavisinin retrospektif incelenmesi

Current Medical Imaging Formerly Current Medical Imaging Reviews, 2021
Peptit Reseptör Radyonüklit Tedavisi (PRRNT) tümöre spesifik reseptörlere afinitesi yüksek radyo işaretli peptitlerin sistemik olarak intravenöz yol ile uygulanmasıyla gerçekleştirilen hedefe yönelik moleküler tedavi yöntemidir. Radyoişaretli somatostatin analoglarından 90Y-DOTA-TOC ([90Y-DOTA0,Tyr3]- octreotide), 177Lu-DOTA-TATE ([177Lu-DOTA0,Tyr3 ...
Naseer Ahmed, Ayesha Ammar, Kahkashan Bashir, Shazia Fatima, Muhammad Zia, Muhammad Adnan Saeed, Muhammad Faheem   +6 more
  +15 more sources

[P108] Radiation safety after 177Lu-dota-tate therapy for neuroendocrine tumors

Physica Medica, 2018
Purpose To evaluate the safety of peptide receptors radionuclide therapy (PRRT) of neuroendocrine tumors after 7.4 GBq 177Lu-DOTA-TATE by measurement of the radiation exposure rates. Methods For each patient the radiation levels (H∗(10)) were measured at 1 meter distance from the patient abdomen.
Josep María Martí-Climent, Elena Prieto, Verónica Morán, Pedro Borja Aguilar, María I. Morales-Lozano, Javier Arbizu   +5 more
openaire   +1 more source

[Treatment of Gastroenteropancreatic Neuroendocrine Tumors with 177Lu-DOTA-TATE: Experience of the Portuguese Institute of Oncology in Porto].

Acta medica portuguesa, 2018
The purpose of this article is to report the experience of the Portuguese Institute of Oncology - Porto in the treatment of gastroenteropancreatic neuroendocrine tumors with 177Lu-DOTA-TATE, regarding the safety and efficacy of this treatment modality.A retrospective analysis of clinical reports of patients with gastroenteropancreatic neuroendocrine ...
Inês Lucena, Sampaio, Henrique Vara, Luiz, Liliana Sobral, Violante, Ana Paula, Santos, Luís, Antunes, Isabel, Torres, Cristina, Sanches, Isabel, Azevedo, Hugo, Duarte   +8 more
openaire   +4 more sources

The peptide-receptor radinuclide therapy with radiopharmaceutical 177Lu-DOTA-TATE.

Journal of oncology: diagnostic radiology and radiotherapy
Introduction: Since 2016, peptide-receptor radionuclide therapy (PRRT) with 177Lu-labeled somatostatin analogues has become a recognized treatment option in the second or third line of patients with progressive differentiated (grade G1–2) gastroentero pancreatic neuroendocrine tumors (GEP-NET) with radiopharmaceutical 177Lu-DOTA-TATE.
A. Yu. Shurinov, V. V. Krylov, E. V. Borodavina, N. V. Severskaya   +3 more
openaire   +1 more source